Construction of New Plant Investment Worth $11 Million Secured by ADC Bio for Bioconjugation Facility
ADC Biotechnology plans to construct a facility at its new site in the UK. The plant is expected to support manufacturing in all clinical phases and small-scale commercial production of ADCs.
Wales/UK – ADC Biotechnology (ADC Bio) has recently announced that it has secured investment for the construction of a $11 million bioconjugation facility at its new site in Deeside, North Wales, UK. The company is a specialist antibody drug conjugate (ADC) contract services company with proprietary conjugation technology that has been designed to overcome process and aggregation challenges during the development of new ADCs.
The 6,500 sq m facility is scheduled to be operational by December 2018 and is expected to support manufacturing in all clinical phases and small-scale commercial production of ADCs. The new integrated facility will enable ADC Bio to complement its long established technical services business that provides small scale R&D through to pre-clinical testing, with three on site laboratories and analytical testing capabilities.
The purpose-built, dual stream bioconjugation facility will provide a suite of capabilities ranging from R&D technical services, quality control, QA, warehousing, and process development through to manufacturing – all of which will occupy just 50% of the unit’s footprint. Consequently, ADC Bio will have free capacity to upscale quickly from early clinical phases into late phase and commercial manufacturing within the same footprint at the new facility.
Subsequent phases are planned for 2018 onwards and will add further capacity for large scale clinical and commercial, and potentially, dosage form production (fill/finish).